RARE

Ultragenyx

NASDAQ: RARE · HEALTHCARE · BIOTECHNOLOGY

$17.20

+2.69% today

Updated 2026-10-28

Market cap

$1.50B

P/E ratio

—

P/S ratio

2.09x

EPS (TTM)

$-5.83

Dividend yield

—

52W range

$13 – $40

Volume

4.8M

Market cap

$1.50B

P/E ratio

—

P/S ratio

2.09x

EPS (TTM)

$-5.83

Dividend yield

—

52W range

$13 – $40

Volume

4.8M

Ultragenyx (RARE) Financial Forecast & Price Target 2030

Revenue-driven projection model with historical context.

Price target summary

Current price

$17.20

12-Month target

—

2030 Target

—

Intrinsic (DCF)

—

Financial forecast

Metric	2021	2022	2023	2024	2025
Revenue	$0.4B	$0.4B	$0.4B	$0.6B	$0.7B
EPS	—	—	—	—	—

CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -81.70%

Methodology

CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.